Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAX-8
- Development stage
- Unknown
- Lead developer
- Guangzhou Zaiji Medical Technology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MAX-8 is a small-molecule radioligand therapy (RLT) developed by Guangzhou Zaiji Medical Technology (Maxinovel). It is designed to target Fibroblast Activation Protein (FAP), a cell-surface protease that is highly expressed on cancer-associated fibroblasts (CAFs) within the stroma of various solid tumors, while maintaining low expression in most normal adult tissues. By specifically binding to FAP, MAX-8 delivers a therapeutic radioactive isotope directly to the tumor microenvironment, facilitating targeted irradiation that induces DNA damage and subsequent cell death in both tumor cells and the supporting stroma. The drug is currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors.
- Other names
- MAX-8MAX8MAX 8
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on MAX-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAX-8.